Nalgesin S (Naproxen Sodium)

Naproxen sodium works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. This inhibition reduces the production of prostaglandins, which are mediators that cause pain, swelling, and fever. Lower prostaglandin levels result in the analgesic, anti‑inflammatory, and antipyretic effects observed with the drug.

The specific dose of Nalgesin S is determined by the prescribing healthcare professional based on the individual’s condition, age, weight, and response to therapy. Dosage regimens may vary, and patients should follow the prescriber’s instructions without altering the amount or frequency on their own.

Safety data for naproxen sodium in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider. Breastfeeding mothers should consult their clinician before use.

To request Nalgesin S, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then provides pricing, availability, shipping details, and any necessary import documentation.

Nalgesin S (naproxen sodium) and ibuprofen are both NSAIDs with similar mechanisms, but naproxen has a longer half‑life, allowing less frequent dosing. Both share comparable efficacy for pain and inflammation, yet individual tolerability, gastrointestinal risk, and cardiovascular profile may differ, so clinicians choose based on patient‑specific factors.

Nalgesin S should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the product out of reach of children and avoid exposure to direct sunlight or humidity, which could affect tablet integrity.

Nalgesin S is administered orally. The tablets should be swallowed whole with a full glass of water, preferably with food or milk to lessen gastrointestinal irritation. Patients should not crush, chew, or split the tablets unless specifically instructed by a healthcare professional.

Serious risks include gastrointestinal bleeding or ulcer perforation, renal impairment, cardiovascular events such as heart attack or stroke, severe skin reactions like Stevens‑Johnson syndrome, and liver injury. Patients should seek immediate medical attention if they notice black stools, sudden kidney problems, chest pain, or unexplained rash.

Nalgesin S should be avoided in individuals with known hypersensitivity to naproxen or other NSAIDs, active gastrointestinal ulceration, severe heart failure, uncontrolled hypertension, or significant renal or hepatic impairment. It is also contraindicated in patients who have experienced a recent myocardial infarction or stroke without medical guidance.